Immunomodulatory Activity of SGI-110, a Second Generation Hypomethylating Agent
نویسندگان
چکیده
منابع مشابه
Structure Exploring, IR and UV Spectroscopic Properties of Pomalidomide as a Second-generation of Immunomodulatory Agent
In this article, the optimized geometry, IR and UV spectra, frontier orbital analysis, natural bond orbital (NBO) analyses, and thermodynamic parameters of pomalidomide were investigated. The calculated structural parameters and stretching frequencies values are compared with experimentalvalues of the investigated compound. Also, the relations of the thermodynamic functions vs.temperatures were...
متن کاملImmunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment
Aberrant DNA hypermethylation favors tumor escape from host’s immune recognition by decreasing the expression of tumor-associated antigens (TAA) (e.g., cancer testis antigens (CTA)), HLA, co-stimulatory molecules that are all required for efficient immune recognition of cancer cells. Thus, increased levels of DNA methylation in cancer cells might contribute to reduced clinical efficacy of immun...
متن کاملEfficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a deadly malignancy characterized at the epigenetic level by global DNA hypomethylation and focal hypermethylation on the promoter of tumor suppressor genes. In most cases it develops on a background of liver steatohepatitis, fibrosis, and cirrhosis. Guadecitabine (SGI-110) is a second-generation hypomethylating agent, which inhibits DNA methyltransferases. Gua...
متن کاملImmunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
We aimed to determine the effect of SGI-110 on methylation and expression of the cancer testis antigens (CTAs) NY-ESO-1 and MAGE-A in epithelial ovarian cancer (EOC) cells in vitro and in vivo and to establish the impact of SGI-110 on expression of major histocompatibility (MHC) class I and Intracellular Adhesion Molecule 1 (ICAM-1) on EOC cells, and on recognition of EOC cells by NY-ESO-1-spec...
متن کاملGuadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.
Promoter DNA hypermethylation is an important biomarker of hepatocellular carcinoma (HCC), supporting the potential utility of demethylating agents in this disease. Guadecitabine (SGI-110) is a second-generation hypomethylating agent formulated as a dinucleotide of decitabine and deoxyguanosine that yields longer half-life and more extended decitabine exposure than decitabine IV infusion. Here ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2013
ISSN: 0923-7534
DOI: 10.1093/annonc/mdt042.12